Ra Medical Granted Patent for Catheters With Expanded Ablation Area

Ra Medical Systems Inc. has expanded its patent portfolio.

The U.S. Patent and Trademark Office has granted the company a patent for liquid-filled laser ablation catheters with expanded distal optical windows. U.S. patent 11,284,941 (the ’941 patent), titled “Laser Ablation Catheters Having Expanded Distal Tip Windows for Efficient Tissue Ablation,” describes a catheter with an increased ablation surface area at the distal catheter tip. This is the eleventh U.S. patent issued to Ra Medical and is a natural evolution in the patent coverage of the company’s DABRA technology.
 
“The design covered by this patent is important because it allows us to achieve an increased ablation area without increasing the overall catheter profile. We believe this will make it easier for us to develop a family of products to address larger diameter vessels using the same base platform technology. The patent marks another milestone in our intellectual property strategy to fortify our competitive position both now and in the future,” said Will McGuire, Ra Medical Systems CEO.
 
Ra Medical Systems manufactures the DABRA excimer laser and catheters for the treatment of certain vascular diseases. DABRA has been cleared by the U.S. Food and Drug Administration for crossing chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease and has an intended use for ablating a channel in occlusive peripheral vascular disease. In addition, DABRA has been granted CE mark clearance for the endovascular treatment of infrainguinal arteries via atherectomy and for crossing total occlusions. DABRA excimer lasers and catheters are manufactured in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in clean room environments.